Quick Answer
Akari Therapeutics Plc reported Net Income of -$17.30 million for fiscal year 2025.
Akari Therapeutics Plc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$17.30M | +12.6% |
| 2024 | -$19.79M | -97.8% |
| 2023 | -$10.01M | +43.6% |
| 2022 | -$17.75M | -1.9% |
| 2021 | -$17.42M | -2.0% |
| 2020 | -$17.08M | -1.4% |
| 2019 | -$16.85M | +17.8% |
| 2018 | -$20.50M | +42.1% |
| 2017 | -$35.40M | -95.1% |
| 2016 | -$18.14M | +60.0% |
| 2015 | -$45.32M | -2226.9% |
| 2014 | -$1.95M | +46.2% |
| 2013 | -$3.62M | +15.2% |
| 2012 | -$4.27M | -101.4% |
| 2011 | -$2.12M | -213.9% |
| 2010 | -$675.0K | +33.3% |
| 2009 | -$1.01M | +29.5% |
| 2008 | -$1.44M | +54.2% |
| 2007 | -$3.13M | -77.0% |
| 2006 | -$1.77M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.40M | -121.1% | -237.7% |
| June 30, 2025 | -$1.90M | +74.9% | +48.9% |
| March 31, 2025 | -$3.71M | +33.4% | -28.0% |
| September 30, 2024 | -$2.90M | -0.8% | +61.7% |
| June 30, 2024 | -$7.56M | -88.9% | -35.8% |
| March 31, 2024 | -$5.57M | -656.0% | -93.9% |
| September 30, 2023 | -$2.87M | — | +28.2% |
| June 30, 2023 | -$4.00M | — | -499.6% |
- Akari Therapeutics Plc showed an increase of +12.6% in Net Income compared to the prior fiscal year.
- Over the 2006–2025 period, Akari Therapeutics Plc’s net income has declined by 877.8% (from -$1.77 million to -$17.30 million).
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: